- Radiopharm Theranostics, dual-listed on NASDAQ with ticker RADX since **December 2024**, specializes in radiopharmaceutical imaging and therapies, focusing on highly differentiated mechanisms of action such as PD-L1, HER2, and B7-H3.  **[0000084129_2232089_0]** 
- The company expects to have **five molecules in clinical stage by the end of 2025**.  **[0000084129_2232089_1]**  Its lead imaging agent, RAD101 for brain metastasis, is in Phase IIB, with top-line results anticipated by **Q1 2026** and full results by **Q3 2026**.  **[0000084129_2232089_1]** **[0000084129_2232089_4]** 
- RAD101 has an estimated market potential of **over $500 million in yearly sales in the US alone**, with some internal projections suggesting it could reach **$500-$700 million**.  **[0000084129_2232089_2]** **[0000084129_2232089_5]** 
- Radiopharm Theranostics maintains strategic partnerships, including a co-development agreement with **Lantheus**, which is also its largest shareholder with approximately **12%** ownership, and a joint venture with **MD Anderson Cancer Center** for new radiopharmaceutical development.  **[0000084129_2232089_0]** **[0000084129_2232089_4]** 
- A recent capital raise in October 2025 has extended the company's cash runway into **Q1 2027**.  **[0000084129_2232089_0]** **[0000084129_2232089_3]** **[0000084129_2232089_5]**

Company not found (RAD)